RCS - Ondine Biomedical - Ondine shortlisted for HSJ Partnership Award

Ondine BiomedicalAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251216:nRSP6532La&default-theme=true

RNS Number : 6532L  Ondine Biomedical Inc.  16 December 2025

16 December 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

Ondine shortlisted for HSJ Partnership Award

 

HSJ Partnership Award Finalists: Ondine Biomedical and Mid Yorkshire Teaching
NHS Trust for Cutting Post-surgical Infection Rates

 

Ondine Biomedical Inc. (AIM: OBI) and Mid Yorkshire Teaching NHS Trust (Mid
Yorks) have been shortlisted for the 'Most Impactful Use of Technology on
Clinical Practice' award at the prestigious 2026 HSJ Partnership Awards,
following the successful implementation of Ondine's Steriwave(®) nasal
decolonisation technology.

 

This award recognises the exceptional contributions from companies and
technology partners that work with NHS organisations to implement solutions
that are delivering meaningful improvements in clinical practice and patient
outcomes.

 

Introduced to reduce surgical site infections (SSI) in patients undergoing hip
and knee replacement surgeries at Mid Yorks' Pontefract and Pinderfields
hospitals, the Steriwave intervention was associated with a 71% reduction in
SSI over a six-month period, along with significant cost savings and tangible
improvements in patient outcomes.

Since the initial pilot, a number of major hospitals across England are using
or evaluating Steriwave across multiple specialties, including ENT,
neurosurgery, cardiac, orthopaedic, and spinal surgery, as well as in the ICU,
where immunocompromised patients are particularly vulnerable to infection.

Growing recognition of the importance of nasal decolonisation-with the nose a
major reservoir of pathogens-has coincided with rising antimicrobial
resistance, which is reducing the effectiveness of mupirocin, the current
standard of care. Mupirocin also has poor compliance, requiring twice-daily
application for five days prior to surgery. In contrast, a single
pre-operative Steriwave treatment rapidly destroys all classes of pathogens
without generating resistance, offering an effective, antibiotic-sparing
alternative.

Real-world data from Mid Yorks demonstrated that, in a standardised cohort of
1,000 people, Steriwave prevents an additional 9.8 SSIs compared to standard
of care alone and reduces total hospital bed days by 139. Using this data, an
independent health-economic analysis by the York Health Economics Consortium
(YHEC) found that the NHS can save £1.49 to £2.38 for every £1 spent on
Steriwave to prevent SSI across major surgical specialties. With £38 to £107
net savings per operation, Steriwave could generate up to £200 million in
annual savings across UK hospitals.

A broader literature-based costing analysis by YHEC further validated these
benefits:

·      Overall Surgeries (hip, knee, spinal, cardiac, vascular):  net
savings of £107,530 per 1,000 patients (£2.38 saved for every £1 spent).

·      Cardiac Surgeries: the largest net savings, up to £228,090 per
1,000 patients (£3.92 saved for every £1 spent).

·      Hip and Knee Surgeries: net savings of approximately £86,650 and
£84,430 per 1,000 patients respectively (£2.10 saved for every £1 spent).

 

Carolyn Cross, CEO of Ondine:

"We are pleased to be recognised for advancing patient welfare in the UK with
our non-antibiotic nasal decolonisation therapy. This recognition highlights
the importance of preventing potentially devastating post-surgical infections
and reducing the UK's 6+ million patients surgical wait list by avoiding
costly readmissions. Congratulations to Dr Stuart Bond and his team for
introducing Steriwave to the NHS, demonstrating its clinical benefits amid
rising antibiotic resistance and generating interest in the UK and abroad."

 

Dr Stuart Bond, Consultant Antimicrobial Pharmacist and Director of Innovation
at Mid Yorkshire Teaching NHS Trust:

"Being named a finalist is a testament to the hard work and dedication of our
team as well as our commitment to innovation to improve patient outcomes.
Patient safety is at the heart of everything we do, and we are proud to be
recognised at a national level."

 

The shortlisting follows a rigorous judging process conducted by a panel of
experts and highly influential and respected figures within the healthcare
community.

 

Steriwave nasal photodisinfection is a non-invasive and painless treatment
that uses a proprietary light-activated photosensitive agent to destroy
harmful bacteria, viruses, and fungi-including antibiotic-resistant strains-in
the nasal passages. The procedure takes five minutes and, unlike antibiotics,
is effective immediately and allows the normal nasal microbiome to recover
quickly, without fostering antimicrobial resistance, offering a powerful tool
in the fight against healthcare-associated infections.

 

Organised by the Health Service Journal (HSJ), the HSJ Partnership Awards are
among the most recognised and respected honours in UK healthcare. They
celebrate outstanding collaborations between the NHS and its partners that
deliver measurable improvements in patient care, efficiency and value.
Shortlisted entries undergo rigorous assessment by senior NHS leaders and
reflect work that is already demonstrating real-world impact.

 

Winners will be announced at the awards ceremony on 19 March 2026, an event
that celebrates excellence, promotes best practice, and recognises the people
and projects driving improved outcomes for patients nationwide. Recognition at
the HSJ Partnership Awards highlights the strength and effectiveness of a
partnership and raises its profile across the NHS and beyond, reinforcing the
credibility and impact of the work being celebrated.

 

For healthcare providers in the UK interested in Steriwave(®), the technology
is available through Ondine's distribution partner, Mölnlycke Health Care, a
global leader in medical solutions. For more information contact: Healthcare
Professionals Contact (https://www.molnlycke.com/en-gb/contact/) or
info.uk@molnlycke.com (mailto:info.uk@molnlycke.com) , or call +44 0800 917
4918.

 

 

Enquiries:

 

 Ondine Biomedical Inc.                                            www.ondinebio.com
 Carolyn Cross, CEO                                                +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson                                     +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                                     +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                                  +44 (0)77 1000 5910

 

 

About Ondine Biomedical Inc.

 

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

 

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved
for nasal decolonisation in Canada, Australia, Mexico and several other
countries under the name Steriwave(®). In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track status by the
FDA and is currently undergoing clinical trials for regulatory approval.
Products beyond nasal photodisinfection include therapies for a variety of
medical indications such as chronic sinusitis, ventilator-associated
pneumonia, burns and other indications.

 

About Mölnlycke Health Care 

 

Mölnlycke Health Care is a world-leading MedTech company that specialises in
innovative solutions for wound care and surgical procedures. Mölnlycke
products and solutions are used daily by hospitals, health care providers and
patients in over 100 countries around the world. Founded in 1849, Mölnlycke
is owned by Investor AB and headquartered in Sweden. www.molnlycke.com
(http://www.molnlycke.com/)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUVSBRVUUUAAA



            Copyright 2019 Regulatory News Service, all rights reserved